Imperial College London
Alternate

ProfessorSebastianJohnston

Faculty of Medicine, National Heart & Lung Institute

Asthma UK Clinical Chair
 
 
 
//

Contact

 

+44 (0)7931 376 544s.johnston

 
 
//

Assistant

 

Mr Christophe Tytgat +44 (0)20 7594 3849

 
//

Location

 

343Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Eccles:2015:10.1186/s12931-015-0281-8,
author = {Eccles, R and Winther, B and Johnston, SL and Robinson, P and Trampisch, M and Koelsch, S},
doi = {10.1186/s12931-015-0281-8},
journal = {Respiratory Research},
title = {Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial},
url = {http://dx.doi.org/10.1186/s12931-015-0281-8},
volume = {16},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ota-carrageenan (I-C) is active against respiratory viruses in vitro and was effective as nasal spray in three previousclinical trials. The current trial served to further investigate I-C in patients with early common cold symptoms.Methods: This randomized, placebo-controlled, double-blind phase IV trial was conducted in 200 adult patientswith self-diagnosed colds of <48 h’ duration that were confirmed by baseline cold symptom scores. Patients wereto self-administer 0.12 % I-C or placebo spray (NaCl 0.5 %) four times daily for four to ten days and record symptominformation for ten days. Common respiratory viruses were quantified by RT-PCR during pretreatment and on Day 3or 4. The primary endpoint was the mean total symptom score (TSS) of eight cold symptoms on Days 2–4 (TSS2–4).Results: Patients in both treatment groups had similar baseline TSSs (mean TSS: 6.75 for I-C and 6.79 for placebo).Viruses were detected in baseline samples from 53 of 98 I-C patients (54.1 %) and 54 of 97 placebo patients(55.7 %). Mean ± SE for TSS2–4 was 5.78 ± 0.25 for I-C patients and 6.39 ± 0.25 for placebo (p = 0.0895). Exploratoryanalyses after unblinding (TSS2–4 excluding a patient with aberrantly high symptom scores [TSS2–4, ex 1pt]; mean ofTSS over Days 1–4 [TSS1–4]; change in TSS1–4 relative to baseline [TSS1–4, rel]) demonstrated treatment differences infavor of I-C (p = 0.0364, p = 0.0495 and p = 0.0421, respectively). For patients with quantifiable rhinovirus/enterovirusat baseline, there was a trend towards greater reduction of virus load at Day 3 or 4 (p = 0.0958; I-C: 90.2 %reduction in viral load; placebo: 72.0 %). Treatments were well tolerated with no differences in adverse event rates.Conclusions: The primary endpoint did not demonstrate a statistically significant difference between I-C andplacebo but showed a trend towards I-C benefit. Exploratory analyses indicated significant reduction
AU  - Eccles,R
AU  - Winther,B
AU  - Johnston,SL
AU  - Robinson,P
AU  - Trampisch,M
AU  - Koelsch,S
DO  - 10.1186/s12931-015-0281-8
PY  - 2015///
SN  - 1465-993X
TI  - Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial
T2  - Respiratory Research
UR  - http://dx.doi.org/10.1186/s12931-015-0281-8
UR  - http://hdl.handle.net/10044/1/29496
VL  - 16
ER  -
Download